NEW YORK, Jan. 21 - UK-based pharmacogenomics firm DxS has granted non-exclusive rights to its Scorpions genotyping technology to Eurogentec, according to Eurogentec.
Terms of the agreement call for Eurogentec, of Liège, Belgium, to acquire non-exclusive rights to manufacture and supply the technology to the life-science community, excluding agrochemical firms, the company said in a statement.
DxS receives an undisclosed royalty in exchange. Further financial details of the deal remained undisclosed.
The Scorpions technology "involves a single, instant reaction and avoids competing and/or side reactions" and can process up to 100,000 assays per day, according to DxS.
"We are delighted to have concluded this, our first licensing agreement, with a strong, international provider of genomic research solutions," Steve Little, CEO of DxS, said in a statement in released in early January.
Eurogentec, which markets a range of genomic- and proteomic-based tools and technologies, was founded in 1985 as a spin-off of the University of Liège. It has subsidiaries in France, Germany, the UK, the Netherlands, and a branch office in Switzerland.